伊马替尼诱发的慢性粒细胞白血病患者Sweet综合征
Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
作者信息
Ayirookuzhi Sanjay J, Ma Li, Ramshesh Priya, Mills Glenn
机构信息
Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71130, USA.
出版信息
Arch Dermatol. 2005 Mar;141(3):368-70. doi: 10.1001/archderm.141.3.368.
BACKGROUND
Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use.
OBSERVATIONS
We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib.
CONCLUSION
Greater awareness of the adverse effects of imatinib and the characterization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.
背景
甲磺酸伊马替尼已成为目前用于治疗慢性粒细胞白血病（CML）患者的主要化疗药物之一。尽管此前已有关于该药物皮肤反应的记录，但这是首次报道使用该药物引发Sweet综合征。
观察结果
我们报告了1例因使用伊马替尼治疗CML继发Sweet综合征的病例。1名53岁患有CML的非裔美国女性在接受伊马替尼化疗后，先后2次出现符合Sweet综合征的嗜中性皮病。
结论
提高对伊马替尼不良反应的认识及其皮肤不良反应的特征描述，将有助于改善对这些不良反应的监测和治疗。
Zotero 插件